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Under FK 506-based immunosuppression, the entire cadaver 
small bowel except for a few proximal and distal centimeters 
was translated to 17 randomly matched patients, of whom two 
had antigraft cytotoxic antibodies (positive cross-match). Eight 
patients received the intestine only, eight had intestine in con-
tinuity with the liver, and one received a full multivisceral graft 
that included the liver, stomach, and pancreas. One liver-intestine 
recipient died after an intestinal anastomotic leak, sepsis, and 
graft-versus-host disease. The other 16 patients are alive after 
1 to 23 months, in one case after chronic rejection, graft removal, 
and retransplantation. Twelve of the patients have been liberated 
from total parenteral nutrition, including all whose transplan-
tation was 2 months or longer ago. The grafts have supported 
good nutrition, and in children, have allowed growth and weight 
gain. Management of these patients has been difficult and often 
complicated, but the end result has been satisfactory in most 
cases, justifying further clinical trials. The convalescence of the 
eight patients receiving intestine only has been faster and more 
trouble free than after liver-intestine or muItivisceral transplan-
tation, with no greater difficulty in the control of rejection. 
T HE INTESTINE was one of the first organs to be transplanted experimentally,1.2 but the last to be 
engrafted successfully in humans. In spite of nu-
merous attempts between 1964 and 1987,3 there were no 
clinical examples of a functioning intestinal graft until 
November 1987. Then, a 3-year-old girl began a 6-month 
period of enterally supported survival after receiving a 
multivisceral abdominal graft that contained all of the 
hollow abdominal organs plus the liver and pancreas.4 In 
a similar operation 1 year later, Grant et al. 5 transplanted 
the small bowel in continuity with the liver to a recipient 
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who is still alive and eating along with a handful of other 
patients treated with variations of the multi visceral pro-
cedure.6,7 In contrast, there have been only two examples 
oflong survival and function of cadaveric intestinal grafts 
when these were transplanted alone.6,8 
The prospects for progress in this difficult field were 
improved with the demonstration in rat intestinal and 
multivisceral transplant models of the superior therapeutic 
index of the new immunosuppressive drug FK 506.9- 12 
We report here our experience using this drug for one 
recipient of the originally described full multi visceral graft, 
eight recipients ofliver-intestine grafts, and eight patients 
who were given small intestine only. Sixteen of these 17 
patients are alive after 1 to 23 months, and most of them 
are eating. This experience has opened up new options 
for the treatment of end-stage intestinal disease with or 
without liver involvement and seems ~rtain to greatly 
influence the future development and practice of gastro-
enterology. 
Methods 
Case Material 
Recipients. The intestinal diagnosis in 15 of the 17 pa-
tients was short-gut syndrome in which the intestine had 
been resected for a variety of reasons; the intestine in the 
other two recipients had uncorrectable disease (Table 1). 
All of the patients were on total parenteral nutrition (TPN) 
before transplantation for 1 to 132 (40.9 ± 41.9 [standard 
deviation]) months (Table 1) and all had experienced more 
than one episode of sepsis, liver damage, or other TPN-
related complications. 
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Eight of the 17 patients were 21- to 50-year-old adults 
(mean age, 31.9 ± 9), and nine were children who were 
0.6 to 4.3 years of age (Table 1). The full multivisceral 
procedure was in a 32-year-old man with protein S defi-
ciency whose clotting abnormality had caused thrombosis 
of his superior mesenteric artery and celiac axis, with con-
sequent intestinal gangrene. Because the liver is the source 
of protein S,13 its inclusion in the graft was obligatory 
even though hepatic failure was not present. All eight pa-
tients undergoing liver-intestine transplantation (two 
adults, six children) had advanced hepatic disease with 
serum total bilirubin concentration from 6.3 to 50 mg/ 
dL. The eight patients (five adults, three children) given 
isolated small bowel grafts were jaundice free, although 
most had minor liver function abnormalities. 
Transplantation Procedures 
Donors. Cadaveric donors of similar or smaller size were 
selected, all being ABO blood group identical with the 
respective recipients. Human leukocyte antigen matching 
was random and uniformly poor. The Iymphocytotoxic 
cross-match was positive in two patients. 
The principles l4 as well as details l5 of the donor oper-
ations have been described elsewhere and included an 
effort at selective bacterial and fungal decontamination. 
The contents of the intestinal lumen were not mechani-
cally washed during the donor operation or afterward. 
Instead, the proximal and distal ends of the intestine were 
sealed with a stapling machine, carrying and transplanting 
the succus entericus to the recipient. Initial cooling of the 
graft was by infusion with cold University of Wisconsin 
(UW) solution, the volume of which was limited to 1 L 
in adult donors to prevent infusion injury. 15 Cold ischemia 
times were 2.8 to 10.6 hours (Table I). For reasons dis-
cussed elsewhere,14 no effort was made to alter the lym-
phoreticular (immunologic) component of the graft with 
antilymphoid agents, irradiation, or other means. 
FIG. 1. Isolated small bowel trans, 
plantation. (A) Donor operation; 
full, length vascular pedicle of the 
SMA (with Carrel patch) and the 
SMV. If both vessels are divided 
more distally, they can be lengthened 
on the back table with arterial and 
venous grafts (insert). (B) Recipient 
operations. Anastomosis of full, 
length SMA to the aorta and the an, 
gled end of the SMV to the portal 
vein. Alternative method with which 
the SMV is anastomosed to the re' 
cipient SMV inferior to the pancreas. 
(Lower insert) Option of SMV 
drainage into the inferior vena cava 
(upper insert). 
Recipients. The small intestinal graft with or without 
the liver included its entire length except for discarded 
short segments of proximal jejunum and distal ileum. 
When transplanted alone, the small bowel graft was based 
on a vascular pedicle of superior mesenteric (or skeleton-
ized portal) vein and the superior mesenteric artery with 
or without an aortic Carrel patch (Fig. I A). The exact 
method of revascular reconstruction and the difficulty of 
its accomplishment depended on the findings in the re-
cipient, which were distorted in most cases by multiple 
previous intra-abdominal operations. Various options 
used for vascular reconstruction are shown in Figure I B. 
The superior mesenteric venous return was directed into 
the recipients pOlial or superior mesenteric vein so that 
it perfused the native liver in all isolated small bowel en-
graftments except for the intestinal retransplantation in 
patient I, where it was necessary to anastomose the su-
perior mesenteric vein of the graft to the inferior vena 
cava (Fig. 1 B insert). 
The vascular reconstructions for the liver-intestine and 
multivisceral procedures were performed as shown in 
Figures 2 and 3 with the venous drainage into the graft 
retrohepatic inferior vena cava. This segment of graft vena 
cava was used to replace retrohepatic vena caval segment 
of the host if this was excised during the recipient hepa-
tectomy (Fig. 3B) or it was anastomosed piggy-back to 
the skeletonized recipient vena cava if the segment could 
be preserved. 14 
Reconstruction of the gastrointestinal tract was with 
conventional techniques. In the first five cases, both ends 
of the intestinal graft were exteriorized by the "chimney" 
method, anastomosing the recipient intestines to the side 
of the graft nearby the chimney enterostomy. In the later 
cases, a tube jejunostomy was used proximally instead of 
a chimney (Figs. 1 B, 2B). When the recipients were able 
to maintain nutrition orally or with tube feedings, the 
enterostomy or enterostomies were taken down with an 
extraperitoneal technique. Biliary reconstruction was 
B 
I' . 1 <., ,., 
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performed by Roux-en-y choledochojejunostomy in the 
liver-intestine recipients (Fig. 2B). Cholecystectomy was 
carried out in all native (Fig. I) or allograft livers (Figs. 2 
and 3). 
A1 anagemenl 
Immunosuppression. FK 506 (0.1 to 0.15 mg/kg/day) 
by continuous intravenous infusion was begun immedi-
ately after graft revascularization. When enteral feeding 
was started, FK 506 was switched to a twice-daily oral 
formulation with several days of overlap. Plasma levels 
of FK 506 (trough target, 1 ng/mL) were measured daily 
during the hospital stay, 2 or 3 times/week for the first 3 
months, and at longer intervals thereafter. 
Methylprednisolone also was started intraoperatively 
(first dose of 200-mg bolus) and rapidly weaned by dec-
rements of 40 mg/day over the next 5 days to 20 mg/day. 
Prostaglandin EI (prostin) at 0.6 to 0.8 jig/kg/hour, was 
began intraoperatively in the last nine patients and con-
tinued for 7 to 14 days. The FK 506-prednisone-prosta-
glandin cocktail has given superior results in liver trans-
plant patients, including those with positive cytotoxic 
cross-matches. 16 
Rejection was treated with an upward dose adjustment 
ofFK 506 when this was possible without nephrotoxicity, 
augmentation of steroids, and OKT3 when necessary.17 
Infection. The same kind of selective decontamination 
used in the donor was begun before operation in the re-
cipient and continued for 4 weeks after transplantation. 
Systemic antibiotics were given for the first 5 days ac-
FIG. 2. (A) Small bowel-liver allo-
graft. Note the continuity of donor 
portal vein. (8) Recipient operation. 
Carrel patch containing the origin of 
the SMA and the celiac axis is anas-
tomosed to the aorta. Ideally, the 
venous return from residual 
splanchnic viscera of the rccipient is 
routcd by vascular anastomosis into 
the graft portal vein. Numerous op-
tions of graft rearterialization and 
venous drainage have been described 
elsewhere. 14 
cording to the results of frequent cultures of the blood, 
stool, urine, sputum, wound exudate, and peritoneal dis-
charge. Chronic virus and protozoal prophylaxis was with 
acyclovir (for cytomegalovirus) and Bactrim (Roche Lab-
oratories, Nutley, NJ; for Pneumocystis carinii). 
Nutrition. Total parenteral nutrition was tapered grad-
ually when enteral feeding with a jejunal tube was com-
menced with Peptamen (Clintec Nutrition Co., Deerfield, 
IL), an isotonic elemental diet that contains peptide-based 
protein, medium-chain triglycerides, and glutamine. 
Later, Peptamen was converted in children to. Compleat 
(Sandoz, East Hanover, NJ), a lactose- and gluten-free 
diet that contains dietary fibers to promote normalization 
of intestinal motility function. 
lvlonitoring 
Rejection. When the diagnosis was suspected clinically, 
endoscopy was performed and mucosal biopsies were ob-
tained for histopathologic analysis. Adjustments in im-
munosuppression were dependent mainly on the biospy 
findings in a decision-making process summarized in Ta-
ble 2. 
Graft Function. Standard liver and pancreas function 
tests were used to follow the function of these solid organs. 
The transplanted and host hollow viscera were studied 
with repeated endoscopy. Upper gastrointestinal series 
with barium meal were performed periodically to deter-
mine changes of mucosal foldings and the duration of 
gastric emptying and intestinal transit time. Absorption 
of d-xylose and fat was measured with the methods of 
Breiter et al. 18 and Amenta,19 respectively. Body weight 
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FIG. 3. Multivisceral allograft (Al 
before and (B) after transplantation. 
Splenectomy is performed on the 
back table. In this case the Carrel 
patch with the superior mesenteric 
artery and celiac axis origins has been 
used to cap a free graft of donor tho-
racic aorta that has been used as a 
conduit. This is only one of several 
options that the operator should be 
prepared to exercise. 14 
A 
as well as serum concentrations of protein, albumin, vi-
tamins, minerals, and trace elements were measured fre-
quently. 
Histopathologic Studies 
Specimens taken at serial endoscopies, exploratory lap-
arotomy, stomal closure, or at the time of graft removal 
were fixed with buffered formalin and stained with he-
matoxylin-eosin. The histopathologic diagnosis of acute 
rejection was made when one or more findings listed in 
Table 2 and shown in Figure 4 were demonstrated. The 
diagnosis of chronic rejection (Fig. 5) could be made with 
certainty only with full-thickness sections of the resected 
graft. Donor-derived lymphocytes in frozen skin tissues 
were detected in case 6 with the V-probe karyotyping 
methods. 
TABLE 2. Monitoring of lntestinaf Graft Rejection and Treatment 
Rejection Clinical Findings Endoscopic Findings Mucosal Biopsy Findings 
-------------------------------------------------------------------------------
Acute 
Mild to 
moderate 
Severe 
Chronic 
Fever 
Abdominal pain 
Vomiting 
Increase of stomal 
output 
Watery diarrhea 
Ileus 
Severe diarrhea 
Abdominal pain 
Abdominal distension 
Metabolic acidosis 
Positive blood culture 
ARDS 
Chronic diarrhea 
Malabsorption 
Progressive weight loss 
Ischemic/dusky mucosa 
Mucosal edema 
Hyperema 
Loss of finc mucosal pattern 
Decrease of peristalsis 
Ulceration 
Mucosal sluffing 
Bleeding 
Loss of peristalsis 
Pseudomem brane 
Hypoperistalsis 
Loss of mucosal fold 
Oily intestinal contents 
Cell infiltration 
Villus blunting 
Cryptitis 
Epithelial cell damage and 
regeneration 
M ucus/paneth cell reduction 
Mucosal hemorrhage 
Mucosal sluffing 
Micro abscess 
Less inl1ammatory cells 
Evident cryptitis 
Regenerative epithelium 
Submucosal fibrosis (suggestive but 
not conclusive)* 
Treatment 
Increase of FK506 dose 
Bolus of steroids 
Recycle 
Increase of FKS06 dose 
Recycle of steroids 
OKT3 
Retransplantation 
* Histologic diagnosis of chronic rejection was made with the resected graft, which showed arteritis obliterance and mucosal abscess. 
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FIG. 4. Histopathology of mucosal biopsy of the intestinal graft. (A) No rejection (H&E, original magnification X 192). (B) Mild rejection (H&E, 
original magnification X480). (C) Severe rejection with massive epithelial slough (H&E, original magnification X480). 
Statistics 
Data are expressed as the mean and standard deviation. 
Group comparisons were made by Student's t test and 
chi square analysis. 
Results 
Survival a/Patients 
All eight isolated small bowel recipients are alive after 
1 to 23 months (Table 1). Three are at home, four are 
still hospitalized in surgical wards, and one (patient 1), 
who lost his graft to chronic rejection at 22 months and 
recently underwent retransplantation, is in the intensive 
care unit. Four of the eight patients have been liberated 
from TPN for 1 to 4 months. 
Seven of the eight small bowel-liver recipients are well 
7 to 21 months after operation. All are TPN free and 
living at home. Patient 7, a 7-month-old girl, died of sepsis 
and multiple organ failure after 23 days. She had devel-
oped Pneumocystis carinii pneumonia on day 2 after op-
eration and an intestinal anastomotic leak on day 4. These 
complications necessitated a reduction of immuno-
suppression. Sixteen days after operation, a skin rash ap-
peared on her lower abdomen. Biopsy of the rash had 
nonspecific histopathologic findings 4 days before her 
death, but I day premortum, repeat biopsy showed clas-
sical findings of graft-versus-host disease. There was single 
keratinocyte necrosis (apoptosis) and infiltration of the 
skin with lymphocytes of donor phenotype. Graft rejection 
was never demonstrated in life. Autopsy was not per-
formed. 
The multivisceral graft recipient (case 10) is ready to 
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FIG. 5. Histopathology of chronic 
rejection of the removed intestinal 
graft. (A) Apoptosis of crypt cells 
(insert, H&E, original magnification 
X480) with sparse inflammatory cell 
infiltration (H&E, original magnifi-
cation X 192). (B) Arteritis obliter-
ance seen at the subserosal layer 
(H&E. X480). 
be discharged on full oral nutrition after staying in the 
intensive care unit for 2 months because of postoperative 
pulmonary insufficiency requiring ventilation. 
Survival of Grafts 
Fifteen of the 17 original grafts remain in place. In 
addition to the liver-intestinal transplant lost by death 
(case 6), an isolated intestinal graft was resected after 22 
months (case 1) and replaced by retransplantation 3 weeks 
later. Recovery from the primary transplantation was 
stormy, with bouts of severe rejection, sepsis, and renal 
failure, and several later episodes of graft rejection asso-
ciated with drug noncompliance. Serial intestinal biopsies 
showed apoptoses of crypt cells with sparse inflammatory 
cell infiltration, suggesting chronic rejection of the graft 
(Fig. 4A). An angiogram performed at 19 months dem-
onstrated narrowing of the peripheral mesenteric arteries, 
which was worse on a repeat study at 22 months, leading 
to the decision for graft enterectomy. The resected graft 
had mucosal ulceration, abscesses, and arteritis obliterance 
(Fig.4B). 
Nongastrointestinal Morbidity 
The early convalescence of most of the recipients was 
prolonged and complicated. Irreversible renal failure de-
veloped in patient 1, necessitati ng cadaver renal trans-
plantation 19 months later, and in patient 10, whose pro-
tein S deficiency already had been responsible for renal 
artery thrombosis and loss of one kidney. A third patient 
(case 9), who had undergone earlier nephrectomy after a 
traffic accident, required temporary hemodialysis after 
transplantation. 
Because of paralysis of the right hemidiaphragm, an 
intestine-liver recipient (patient 5) required respiratory 
support for 300 days. Another child (case 4) with the same 
operation became permanently paraplegic after a lumber 
puncture. An adult (patient 3) underwent femoral arterial 
grafting for treatment of a pseudoaneurysm caused by a 
femoral arterial puncture. 
Gastrointestinal Morbidity 
Rejection. Three patients (cases 6, 7, and 12) had no 
histopathologic evidence of rejection during their follow-
up of23, 234, and 97 days. In the other 14, some evidence 
of acute rejection was first demonstrated with mucosal 
biopsy at a mean postoperative time of 15.5 ± 7.8 days 
(range, 7 to 55). This usually was mild or moderate. Nearly 
total denudation of the mucosa by severe graft rejection, 
however, developed on four occasions in three patients 
(case 1, days 14 and 167; case 4, day 74; case 5, day 137). 
This was reversed with complete healing within 1 to 2 
weeks after a management adjustment. Two courses of 
OKT3 were given each to patients 1 and 10. 
Unexpectedly, the incidence of graft rejection in the 
first 2 months after isolated small bowel transplantation 
was lower than after combined liver-intestine or multior-
gan transplantation (Table 3). In six of the nine grafts 
containing liver and intestine (eight liver-intestine and 
one multi visceral), the incidence of rejection was similar 
in both organs. Rejection was more prevalent in the liver 
----K-~---K-K--K-~ ... --- .. -.. - - .. -.. ~---... ---. ~-K-~-- ... -
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TABLE 3. Comparison oj Early Postoperative Course* in Recipients After Small Bowel Versus Small Bowel/Liver Transplantation 
Caset 
Pediatric 
Adult 
Graft 
ICU stay (days) 
Hospital stay (mo) 
Immunosuppression:j: 
FKS06 (mg/kg/day) 
IV dose 
Oral dose 
Plasma level (ng/ml) 
Steroid (mg/kg/day) 
IV dose 
Oral dose 
Imurane (mg/kg/day) 
PGE! 
No. of patients requiring adjuvant therapy 
Steroid 
Bolus 
Recycle 
OKT3 
Small bowel rejection 
No. of biopsies 
Histologic rejection 
None 
Mild to moderate 
Severe 
Nutrition 
Enteral feeding, started (days)§ 
TPN, stopped§ 
Infectious episodes ll 
Viral 
Bacterial (translocation) 
Fungal (translocation) 
* Findings within 2 months after transplantation. 
t Includes only patients with data for longer than 2 months (small 
bowel cases I, II, 12, 13, and 14~ small bowel-liver cases 2,3.4,5.7. 
8. and 9). 
than in the intestine in the other three patients, however 
(case 2. 83% versus 27%; case 4, 53% versus 21 %; case 5, 
85% versus 57%). On the 38 occasions on which both liver 
and small bowel biopsies were taken simultaneously or 
closely together, 16 (42%) of the dual specimens had no 
sign ofrejection in either organs, nine (24%) had rejection 
in both, nine (23%) had rejection only in the liver, and 
four (11 %) had rejection in the intestine only. 
Injection. Microorganisms were detected in the blood 
in eight patients at 21 occasions: Candida albicans (one 
example), enterococcus fecium/fecalis (six examples), co-
agulase-negative Streptococcus (four), cytomegalovirus 
(three), influenza hemophilus (one), and gram-positive 
cocci (six). Bacterial translocation was proven in four pa-
tients on six occasions, half of which were associated with 
rejection: case I at day 57; case 2 at days 18 and 30; case 
4 at days 7 and 21, and case 11 at day 15. Recipients of 
isolated small bowel were neither more nor less prone to 
infectious complications than the recipients of the com-
plex grafts (Table 3). 
Small Bowel Small Bowel/Liver 
S 7 
3 S 
2 2 
7.6 (S-14) 63 (3-300) 
3.9 (1-12) S.2 (3-10) 
0.09 (0.06-0.12) 0.D7 (0.OS-0.13) 
0.4 (0.2-0.70) 0.2 (0.1-0.5) 
3.0 (1.7-6.2) 1.9 (\'S-2.6) 
0.6 (0.3-1.0) 0.4 (0-1.0) 
0.2 (0-0.3) 0.3 (0-1.2) 
1.0 (0-0.3) 0.2 (0-1.3) 
4 patients I patient 
4 (80%) 7 (100%) 
4 (80%) I (14%) 
I (20%) 0(0%) 
30 29 
26 (87%) 17 (S9%) 
3 (10%) 12 (41%) 
1 (3%) 0(0%) 
8.8 (S-I4) 27.7 (11-37) 
30.5 (14-49) 123.1 (45-210) 
1 
I 4 
3 (2) 7 (3) 
2 (1) 2 
~: Mean value (range). 
§ Statistically significant (p < 0.05). 
II Number of episodes in each group of patients. 
Small Bowel Function 
Nutrition. Total parenteral nutrition was discontinued 
after 14 to 210 days (89.5 ± 69.7), the average period 
being much shorter in isolated small bowel recipients than 
in those with organ combinations (Table 3). All nine pe-
diatric patients had failed to learn (or had forgotten) to 
eat. Oral feeding had to be taught, and patients 5 and 7 
still prefer tube feeding to eating in spite of intensive re-
habilitation. 
Except for patient 6 (who died) or patients 1, 15, 16, 
and 17, who were operated on recently, the other 12 re-
cipients are supported nutritionally solely with their func-
tioning grafts. All recipients followed for more than 3 
months have maintained or gained body weight after 3 
months, with the exception of patient 1, who eventually 
came to retransplantation (Fig. 6). 
Gastrointestinal motility. Gastric emptying in the early 
postoperative period was delayed from 3 to 12 hours in 
half of the recipients studied (7/14), but recovered spon-
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Small Bowel Small Bowel f Liver 
Time In months 
FIG. 6. Body weight changes of the recipients after small bowel trans-
plantation. Numbers indicate cases listed in Table I. The seemingly poorer 
weight gain in the isolated small bowel recipients retlects the more recent 
case accrual and consequent shorter follow-ups. Weight gain in either 
the isolated small bowel or bowel-liver patients did not start until 2 or 
3 months. 
taneously after 4 to 6 months. Ten of these recipients had 
an abnormality of the intestinal graft transit time, which 
was markedly accelerated (less than 1 hour) in seven or 
prolonged (more than 3 hours) in the other three. When 
studied later, these abnormalities were improved. 
Absorption. D-xylose absorption tests performed with 
12 patients 1 to 22 months after operation were normal 
in six, slightly abnormal in five, and poor in one (Fig. 7). 
The amount of the total fecal lipids was usually high at 
early postoperative period, and fat absorption is still ab-
normal in some patients as long as a year after transplan-
tation (Fig. 8). 
Discussion 
There are metabolic and immunologic considerations 
in planning the transplantation of the intra-abdominal 
organs. At one time, it was suspected that rejection would 
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FIG. 7. D-Xylose absorption test in the recipients after small bowel trans-
plantation. Most recent data arc shown (case, postoperative days of the 
study). 
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FIG. 8. Fecal fat excretion of the recipients after small bowel transplan-
tation. Multiplication symbols indicate data from the same patient. 
be ameliorated with primary delivery of a graft's venous 
return through the liver through the portal vein.20 Evi-
dence supporting this hypothesis as it applies to the in-
testine, however, has not been obtained by direct testing 
in rats.21 - 23 Thus, efforts to drain the transplanted intestine 
transportally for immunologic reasons have little justifi-
cation. 
There are significant metabolic reasons, however, to 
try to have transportal venous drainage. Either the native 
or the transplanted liver is subject to adverse Eck fistula 
(portaprival) effects to the extent that the so-called he-
patotrophic factors in the venous effluent from the pan-
creas (principally insulin) and intestine (nutrients and en-
teric hormones) are diverted from it.24-26 Consequently, 
the ability to use techniques that drain the intestinal ve-
nous return transportally was noteworthy. In cases in 
which the intestine was transplanted alone, it was routinely 
possible to route its venous return through the native liver 
instead of resorting to the technically more expedient op-
tion of mesocaval drainageY Similarly, when the intestine 
and liver were transplanted together, the metabolic ob-
jective was systematically met of draining the venous re-
turn from the recipient's pancreas and other residual 
splanchnic organs, through the transplanted liver . 
An important additional question of basic immunologic 
as well as practical surgical interest is how protective (to-
lerogenic) a concomitantly transplanted liver is of other 
organ allografts from the same donor. 10•28,29 Hepatic to-
lerogenicity has been confirmed in numerous experimen-
tal models and could be used as an argument to replace 
the liver as an "expediter" for the intestine even though 
it is normal. 5.7 The persuasiveness of this proposition has 
been enhanced by the rejection in the past of almost all 
reported isolated cadaveric small bowel transplants in hu-
mans. 
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Our experience suggests on the contrary that the less 
draconian procedure of isolated small bowel transplan-
tation is the procedure of choice if the only need is for 
the intestine. This would reserve the multi visceral or liver-
intestinal operations, as has been our policy, for specific 
indications such as coexisting liver failure or a hepatic 
inborn error (exemplified by the protein S deficiency in 
our case 10). Although in no way interdicting the hepatic 
tolerogenicity concept, our results indicate that the im-
munologic advantage of a coexisting liver graft is not an 
obligatory condition for successful intestinal transplan-
tation. In fact, the greater ease, lower expense, and above 
all greater safety of the isolated intestinal procedure 
emerged clearly from our series, which is the first that has 
become available for such analysis. Realization of the 
practicality of isolated intestinal transplantation should 
be an incentive to intervene earlier in selected cases before 
the advent of the poorly understood secondary hepatic 
injury that is associated with TPN. 
The list of indications for isolated intestinal transplan-
tation in addition to the short gut syndrome already is 
emerging and so far in our series has included inflam-
matory bowel (Crohn's) disease, microvillus inclusion 
disease, intestinal pseudo-obstruction, and a nonresectable 
desmoid tumor in a patient with Gardner's syndrome. It 
is too early to predict how good the function will be of 
the chronically tolerated intestinal graft, whether it is 
transplanted alone or as part of an organ complex. Nearly 
normal intestinal allograft function, however, has been 
described in rats lO and pigs. 30 Dogs had the subnormal 
fat and d-xylose absorption detected in some of our pa-
tients,31 but in spite of the im perfect laboratory tests, most 
of the human recipients have had satisfactory nutrition, 
which improved with time. 
The ability to move forward with intestinal transplan-
tation has been facilitated by FK 506, not only because 
this drug has been shown by direct testing to provide more 
potent immunosuppression than cyclosporine for protec-
tion of the intestinal graft,9-12 but also because its absorp-
tion characteristics after oral administration are less in-
fluenced by the presence or absence of bile, bile acids32 
and by the motility and function of the intestine itself. 
The oral doses of FK 506 in long-surviving patients nec-
essary to maintain adequate plasma levels were very little 
different (Table 3) from that in recipients oflivers, hearts, 
or kidney. 
As these and previous trials proceeded, some of the 
assumptions have come into question on which earlier 
clinical trials of intestinal transplantation were based. For 
one thing, the monitoring of rejection has proven to be a 
straightforward exercise, depending on clinical judgment 
and biopsy studies rather than on any kind of special test. 
Our procurement procedures also have evolved toward 
simplicity. Past practices that were omitted included ex-
tensive infusion of cold preservation fluids during pro-
curement, cleaning the lumen of its contents, and ma-
neuvers to weaken the immunologic reactivity of the 
bowel's large lymphoreticular cell population. This last 
policy has not resulted in a high incidence of graft-versus-
host disease, as some had predicted. 
Study of the intestinal graft may help to better under-
stand graft-versus-host disease and its prevention. In rat 
survivors of intestinal or multi visceral transplantation 
under FK 506, it was shown that the lymphoid and den-
dritic cells of the graft were rapidly replaced with similar 
recipient cells, 10 whereas the donor cells migrated to and 
nested in recipient lymphoid and other tissues.33 Appar-
ently these cells are nonreactive in their new locations to 
the alien tissues in which they reside, and cause neither 
rejection nor graft-versus-host disease, providing there is 
effective immunosuppression. The same kind of cell traffic 
and repopulation has been documented in our human 
intestinal and multi visceral recipients6,34 and probably is 
a generic phenomenon with the successful allotransplan-
tation and xenotransplantation of all tissues and organs. 35 
If this latter concept is validated, it will change many con-
cepts and dogmas of transplantation immunology. 
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DISClJSSION 
DR. RONALD W. BUSUTTIL (Los Angeles. California): This presen-
tation represents a major advance in small intestinal transplantation and 
affirms the pioneering position in transplantation of Dr. Starzl and his 
colleagues. 
We also have been interested in small intestinal transplantation at 
UCLA and initiated a program in July of 1991. Our first case that I 
would like to share with you has many similarities to the series reported 
here. Our recipient was a 19-year-old man with a short gut syndrome 
secondary to a stab wound to the superior mesenteric artery. A combined 
liver-small bowel transplant using an ABO-matched, HLA-mismatched 
allograft was performed under quadruple immunosuppression including 
OKT-3. cyclosporine, low-dose Imuran. and steroids. 
The graft was placed orthotopically with portal drainage of the recipient 
directed into the donor's portal vein. Severe rejection of both the liver 
and the intestine occurred on postoperative day 26. Within 24 hours. 
severe mucosal ulcerations developed that went on to sloughing of the 
entire mucosa. 
[Slide 1 This shows you the upper gastrointestinal tract during the bout 
of severe rejection. And you can see there is loss of the feathered edge 
of the mucosa with a pseudomembrane formation. The episode was 
refractory to steroids and anti-lymphocyte preparations but reversed with 
FK506. 
His recovery after this episode of rejection was uneventful and he was 
discharged after 21f, months on total oral feedings and is now under the 
care of our recorder. Dr. Clyde Barker. 
In the interim, we found it very useful to have a jejunal feeding tube 
as was described by Dr. Todo and his colleagues and also to place a 
gastrostomy tube. We encountered a very difficult 2-month period of 
unexplained and refractory gastric paresis, which was also seen, I believe, 
by the Pittsburgh group. This fortunately subsequently resolved. The J-
tubes and the G-tubes, however. were invaluable during this critical period 
for enteral feedings to bypass the stomach. 
Dr. Todo, I would like to ask you three questions. We have also used 
prostaglandin EI in our liver patients. the benefits of which may be 
achieved from its vasodilatory properties, smooth muscle relaxation, and 
mild immunosuppressive properties. Could you expand on how the 
25. Koltun WA, Kirkman RL. Nutritional and metabolic aspects of 
total small bowel transplantation in inbred rats. Transplant Proc 
1987; 19:1120-1122. 
26. Schraut WH, Abraham VS, Lee KW. Portal versus caval venous 
drainage of small bowel allografts: technical and metabolic con-
sequences. Surgery 1986; 99: 193-198. 
27. Tzakis AG, Todo S, Reyes J, et al. Piggyback orthotopic intestinal 
transplantation. Surg Gynecol Obstet (in press). 
28. Caine RY, Sells RA, Pena JR, et al. Induction of immunological 
tolerance by porcine liver allografts. Nature 1969; 223:472-476. 
29. Kamada N. The immunology of experimental liver transplantation 
in the rat. Immunology 1985; 55:369-389. 
30. Grant D, Duff J. Zhong R, et al. Successful intestinal transplantation 
in pgis treated with cyclosporine. Transplantation 1988; 45:279-
284. 
31. Diliz-Perez HS, McClure J, Bedctti C, et al. Successful small bowel 
allotransplantation in dogs with cyclosporine and prednisone. 
Transplantation 1984; 37:126-129. 
32. Furukawa H, Imventarza 0, Venkataramanan R, et al. The effect 
of pile duct ligation and bile diversion on FK 506 pharmacoki-
netics in dogs. Transplantation 1992; 53:722-725. 
33. Murase N, Demetris AJ, Woo J. et al. Lymphocyte traffic and graft-
versus-host disease after fully allogeneic small bowel transplan-
tation. Transplant Proc 1991; 23:3246-3247. 
34. lwaki Y, Starzl TE, Yagihashi A. et al. Replacement of donor lym-
phoid tissue in human small transplant under FK 506 immu-
nosuppression. Lancet 1991; 337:8 I 8-820. 
35. Starzl TE, Demetris AJ. Murase N, et al. Cell migration, chimerism, 
and graft acceptance. Lancet 1992; 339: 1579-1582. 
FK506 prostaglandin cocktail has given superior results and if this spe-
cifically applies only to small bowel grafts? 
Secondly, there are numerous experimental studies confirming the 
difficulty of diagnosing small intestinal rejection given the segmental 
nature of the rejection process. Could you comment on the adequacy 
of mucosal biopsies in your selies for diagnosing small intestinal rejection, 
and did you find any instances of clinical rejection in the presence of 
normal biopsies? 
Third. what is your explanation of the gastric paresis that you saw in 
your patients, and was it related to abnormalities in the jejunal pace-
makers? 
And finally, it is generally acknowledged that the liver provides an 
immunologically favorable environment for other organs transplanted 
from the same donor. In your paper, however, you note that the incidence 
of graft rejection in the first 2 months was lower in isolated intestinal 
grafts versus multivisceral transplants and combined liver-small intestinal 
grafts. Additionally, in three of the nine liver-small bowel grafts. the 
rejection was more severe in the liver than it was in the small intestine. 
Do you have any theory to explain this, and do you think that it is 
probably related to the use of FK506? 
DR. FELIX T. RAPAPORT (Long Island. New York): President Thomp-
son, members, and guests: I enjoyed both papers, and I want to congra-
tulate Dr. Todo on his outstanding presentation of what may well be an 
historic paper. 
Until recently, cluster and intestinal transplants were considered rel-
atively futile. In fact. I remember many years ago, when Tom Starzl first 
presented his cluster procedures here. one of our great leaders. Dr. Long-
mire, arose to question why he bothered. Why did he not just wheel the 
patient from the donor room to the recipient room, and then trade places? 
Well, we have now eome full swing around. With the advent of new 
immunosuppressants, we have gradually seen the so-called "forbidden 
organs" come into the fold and within the range of clinical transplantation. 
This applies to the cluster procedures, to small intestinal transplants, 
and to many other procedures to come. To a large extent, this is due to 
explosive development in our understanding of the immunologic reaction 
at the efferent and afferent arcs, and to the use of increasingly specific 
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immunosuppressive agents to control these elements. FK506 is the new 
prototype; I am sure that many others are still to come. 
I wanted to ask Dr. Todo about something far more basic than this. 
And that is, Dr. Murase in your laboratory has published some fascinating 
data on the traffic of cells between intestinal transplants, in the rats and 
the host, with an almost instantaneous exchange of various cells, especially 
dendritic cells, between donor tissues and the host. I wonder whether 
you have done any similar studies, in humans, in this series of patients. 
I also note that you have now greater succcss with small intestinal 
transplants done alone. Have you looked for donor source Kupffer cells 
in the host, for example? What are your overall thoughts on the induction 
of unresponsiveness as a result of such traffic, following the lines of Dr. 
Barker's studies, for example, with the thymus? 
DR. LUIs O. V ASCONEZ (Birn1ingham, Alabama): I would like to know 
the interval of time between warm ischemia and revascularization. In 
autotransplantation of the intestine, we find that the warm ischemia 
interval is an important factor in preventing at least mucosal necrosis. 
DR. JAMES C. THOMPSON (Galveston, Texas): In line with the last 
question, I would like to ask, what are the two oldest, longest functioning 
grafts, and how are they functioning? 
DR. BVERS W. SHAW, JR. (Omaha, Nebraska): I congratulate Dr. Todo. 
I had the pleasure of making rounds with him about a month ago. We 
should recognize that this is a true clinical series, whereas the rest of us 
have sort of been dabbling with isolated cases in this field. It is amazing 
what progress has been made. It is the first time that true progress has 
been made in this field. 
The matter that concerns all of us, which is obvious from the presen-
tation, is that we do not know what the long-term results are going to 
be. I would like to ask Dr. Todo specifically what his fears are regarding 
the development of chronic rejection and what strategies he might have 
in mind to prevent it. 
DR. S. TODo (Closing discussion): Dr. Busuttil. thank you very much 
for your comments and for showing us your interesting case. I believe 
that the positive results of our intestinal transplantation trial depend 
primarily on the use ofFK506 for post-transplant immunosuppression. 
I also believe, however, that prostaglandin E, administration during the 
immediate postoperative period has played an important role. Prosta-
glandin E, (PGE,) has been shown to possess immunosuppressive qualities 
as well as the ability to protect the kidney from untoward insults. Takaya 
et al. (Transplantation, in press) found that the patients who were cross-
match positive and treated with PGE" after liver transplantation, had 
better patient/graft survival and renal function than those who had a 
positive cross-match but did not receive PGE,. Encouraged by these 
findings, we started to give this agent to intestinal recipients from August 
1991. Administration ofPGE, has made immunosuppressive manage-
ment rather easy, by decreasing the threat of renal dysfunction caused 
by FK506. Incidentally, two of our successfully treated patients had pos-
itive cytotoxic antibody cross-matches with their donors. 
A second crucial improvement, in our experience, is the establishment 
of guidelines for monitoring and treating graft rejection. As you pointed 
out, it has been said that intestinal graft rejection occurs segmentally. 
thereby leading to the frequently expressed opinion that histopathologic 
diagnosis with biopsy samples is unreliable. To overcome this problem, 
we used endoscope-guided biopsies, thus enabling us to identify regions 
that showed significant abnormality. Even with this method, 30% of the 
samples had a false-negative finding when the rejection was mild. There-
fore, we usually take at least three to five biopsies during each endoscopic 
procedure. 
Regarding the question of delayed gastric emptying in intestinal re-
cipients, we have no idea why it occurs. What we do know is that it is 
identified between I and 4 months after transplantation. at the time 
efforts at oral feeding are made, and that it disappears spontaneously at 
around 6 postoperative months. We are now conducting experiments 
in dogs measuring gastrointestinal motility, intestinal transit time, gastric 
emptying time, and neuropeptide hormones to try to establish the caus-
ative factors. 
Concerning the last question by Dr. Busuttil, the finding that the iso-
lated graft recipients had fewer episodes of intestinal graft rejection and 
a better postoperative course than the combined intestine and liver pa-
tients was completely unexpected, because the opposite has been shown 
experimentally. Of course, we have to observe our patients carefully for 
a much longer period to determine if the hepatic graft has a tolerogenic 
effect, but we believe that improved immunosuppressive management 
of our patients has contributed to this unexpected result. The first patient 
of our series who had a stormy course after isolated intestinal transplan-
tation 22 months ago is doing much better this time after intestinal 
retransplantation. 
Thank you very much, Dr. Rapaport, for your kind comment and 
question on the cell traffic phenomenon after intestinal transplantation. 
Unfortunately, we did not study this phenomenon in all of our patients, 
but the analysis with the initial four cases and sporadic further cases 
demonstrated that there is exchange of lymphocytes between the graft 
and the recipient (lwaki etal. Lancet 1991; 337:818). Donor cells migrated 
from the graft into systemic circulation of the recipient after transplan-
tation, representing 5')" to 10% of total lymphocytes in the peripheral 
venous blood. At the same time, it was shown that lymphocytes in the 
graft were gradually replaced by those of recipient origin. This phenom-
enon, initially demonstrated by Arnaud-Battandier et al. (Transplant 
Proc 1985; 17:1440) and thoroughly studied by Murase et al. (Surgery 
1991; 110:87), has now been shown not to be unique to the intestinal 
graft, but common to every solid organ transplantation. Cell traffic is a 
generic phenomenon. 
Regarding Dr. Vasco nez's question, intestinal preservation is an im-
portant key for successful transplantation. Although the intestine is very 
sensitive to ischemia, the duration of warm ischemia necessary to perform 
the vascular anastomoses does not seem crucial. The time span from 
when the graft is brought up to the operating table to the time of graft 
revascularization is brict~ usually 30 minutes or less. We believe that the 
duration of graft preservation as well as the warm ischemic time are 
critical factors. The grafts that were preserved for more than 7 hours in 
the University of Wisconsin solution tended to show more preservation 
injury by histologic study of postreperfusion mucosal biopsies. 
Regarding the question by Dr. Shaw, the prevention of chronic intes-
tinal rejection is one of the objectives currently being pursued in our 
experimental transplantation laboratory. Although the new immuno-
suppressive agent, FKS06, has made it feasible to perform clinical in-
testinal transplantation, I believe that we have to bring in a third drug 
to refine our immunosuppressive regimen, partly for that purpose. We 
are now doing experiments to control chronic or humoral rejection, by 
combining FK506 with other newly developed agents that suppress both 
T- and B-cell proliferation by inhibiting DNA synthesis. 
Dr. Thompson, the longest graft survival in our series is 22 months 
after isolated intestinal transplantation and 20 months after intestine 
and liver transplantation. 
